WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups | CIDRAP

SAGE said its third-dose recommendation applies to all vaccines that the WHO has approved for emergency use. They include Pfizer-BioNTech, AstraZeneca-Oxford, Johnson & Johnson, Moderna, Sinopharm, and Sinovac. For Sinopharm and Sinovac, two inactivated vaccines from China, SAGE said a third dose should be offered to people ages 60 and older as part of an extended primary series. It added that a third dose of a different vaccine could be considered, based on vaccine supply and access. However, SAGE urged countries to prioritize 2-dose coverage in that age group, then administer third doses, starting with the oldest age groups. In other vaccine news, Germany-based CureVac today announced that it is withdrawing from regulatory consideration its current COVID-19 vaccine candidate, an mRNA vaccine that uses unmodified RNA, to focus on a second-generation candidate that it is developing with GSK. The company projects that the newer vaccine will be ready for regulatory approval in 2022. The CureVac vaccine had disappointing results in late-stage clinical trials, which suggested an overall efficacy of 48%. In other developments, India’s vaccine advisory group today recommended the cou

Source: WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups | CIDRAP